GSK, a London-based FTSE 100 pharmaceutical company, has temporarily suspended certain diversity, equity and inclusion (DEI) initiatives for its UK employees. This decision stems from the company’s interpretation of US regulatory requirements. The US is GSK’s largest market.
The Guardian reported that the company has also revised its website, removingissued
Free Trial
Register for free to keep reading.
To continue reading this article and unlock full access to GRIP, register now. You’ll enjoy free access to all content until our subscription service launches in early 2026.
- Unlimited access to industry insights
- Stay on top of key rules and regulatory changes with our Rules Navigator
- Ad-free experience with no distractions
- Regular podcasts from trusted external experts
- Fresh compliance and regulatory content every day